Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

Healthcare Drug Manufacturers - Specialty & Generic
"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

MERUS LABS INTERNATIONAL INC > Acquisition
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by ydakhelon May 23, 2015 2:46am
144 Views
Post# 23756936

RE:RE:RE:RE:Acquisition

RE:RE:RE:RE:AcquisitionThe question I have is why did Novartis sell these products if they are generating that much revenue? Sometimes these companies sell their products when the patent is about to expire. Is this the case here? I am not sure. I hope Merus management did their due diligence on this acquistion. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities